Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study

BACKGROUND: People with severe mental illness are two to three times more likely to be overweight or have obesity than the general population and this is associated with significant morbidity and premature mortality. Liraglutide 3 mg is a once daily injectable GLP-1 receptor agonist that is licensed...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnard-Kelly, Katharine, Whicher, Clare A., Price, Hermione C., Phiri, Peter, Rathod, Shanaya, Asher, Carolyn, Peveler, Robert C., Holt, Richard I. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740474/
https://www.ncbi.nlm.nih.gov/pubmed/34996406
http://dx.doi.org/10.1186/s12888-021-03666-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740474/
https://www.ncbi.nlm.nih.gov/pubmed/34996406
http://dx.doi.org/10.1186/s12888-021-03666-5

Ejemplares similares